DS
ADMS

DRW Securities’s Adamas Pharmaceuticals ADMS Stock Holding History

DRW Securities’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-21,800
Closed -$572K – 114
2015
Q2 		$572K Buy
+21,800
New +$424K 0.06% 62

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DRW Securities's ADMS Position: Q3 2015 in Review

DRW Securities sold out of Adamas Pharmaceuticals (ADMS) in Q3 2015, closing a stake of 21,800 shares — an estimated $572K sold.

DRW Securities first reported a position in ADMS in Q2 2015 and held it in 1 quarter. The position peaked at $572K in Q2 2015. 83 funds tracked by Wall St. Rank hold ADMS as of Q3 2015.

  • DRW Securities reported no remaining Adamas Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • DRW Securities sold 21,800 Adamas Pharmaceuticals shares in Q3 2015, an estimated $572K.
  • DRW Securities first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • DRW Securities's Adamas Pharmaceuticals position peaked at $572K in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2015.

Based on DRW Securities's 13F filing for Q3 2015, filed 16 Nov 2015.